Aligos Therapeutics, Inc. (ALGS)
$
5.74
-0.06 (-1.05%)
Key metrics
Financial statements
Free cash flow per share
-9.3965
Market cap
34.2 Million
Price to sales ratio
10.4531
Debt to equity
0.0676
Current ratio
7.5578
Income quality
1.4815
Average inventory
0
ROE
-1.0402
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapeutics to meet the unmet medical needs in viral and liver diseases. The company’s lead drug candidate, ALG-010133, is an s-antigen transport-inhibiting oligonucleotide polymer currently undergoing Phase Ib clinical trials for the treatment of chronic hepatitis B (CHB). Additionally, ALG-000184, a capsid assembly modulator, is in Phase I clinical trials aimed at combating CHB. Other promising developments include ALG-020572, an antisense oligonucleotide designed to prevent HBsAg translation and secretion, alongside ALG-055009, a small molecule THR-ß agonist positioned in the Phase 1a/1b trials for non-alcoholic steatohepatitis (NASH). The company is also advancing its siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, which have shown potent inhibition of HBsAg release from HBV-infected cells. Aligos has established several licensing and collaboration agreements, including partnerships with Luxna Biotech Co., Ltd. for the development of oligonucleotide products targeting the hepatitis B virus genome, Emory University for hepatitis B virus capsid assembly modulator technology, and a research agreement with Katholieke Universiteit Leuven focused on developing coronavirus protease inhibitors. Furthermore, a collaboration with Merck is underway to discover and optimize oligonucleotides aimed at treating NASH. The total costs and expenses for the company are $93,099,000.00 reflecting its overall spending. The company recorded an operating income of -$89,154,000.00 demonstrating its earnings from core operations. It incurred an income tax expense of $331,000.00 indicating its tax obligations. The company's stock is identified with the symbol '$ALGS' in the market, and it reported an income before tax of -$130,880,000.00 showcasing its pre-tax profitability. The stock is affordable at $5.74 making it suitable for budget-conscious investors. However, the stock has a low average trading volume of 163,633.00 indicating lower market activity. With a market capitalization of $35,068,378.00 the company is categorized as a small-cap player. Aligos Therapeutics is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, driving innovation and growth.
Is Aligos Therapeutics, Inc. (ALGS) a good investment?
Investing in Aligos Therapeutics, Inc. (ALGS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Aligos Therapeutics, Inc. (ALGS)'s stock forecast?
Analysts predict Aligos Therapeutics, Inc. stock to fluctuate between $3.76 (low) and $46.80 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Aligos Therapeutics, Inc.'s market capitalization?
As of 2025-05-29, Aligos Therapeutics, Inc.'s market cap is $35,068,378, based on 6,114,800 outstanding shares.
How does Aligos Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Aligos Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Aligos Therapeutics, Inc. (ALGS) stock?
To buy Aligos Therapeutics, Inc. (ALGS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALGS. Place an order (Market, Limit, etc.).
What is the best time to invest in Aligos Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Aligos Therapeutics, Inc. stock ever split?
Aligos Therapeutics, Inc.'s last stock split was 1:25 on 2024-08-19.
How did Aligos Therapeutics, Inc. perform in the last earnings report?
Revenue: $3,945,000 | EPS: -$20.94 | Growth: 494.89%.
Where can I find Aligos Therapeutics, Inc.'s investor relations reports?
Visit https://www.aligos.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Aligos Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Aligos Therapeutics, Inc. stock?
All-time high: $875 (2021-02-17) | All-time low: $3.76 (2025-04-11).
What are the key trends affecting Aligos Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
a day ago
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 2:00pm ET.
globenewswire.com
10 days ago
SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Laura Kavanaugh, JD as Vice President, Head of Legal, effective immediately.
globenewswire.com
14 days ago
SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 26,000 shares of the Company's stock (the “Inducement Grant”) to a newly hired employee on May 13, 2025 (the “Grant Date”), in connection with the commencement of employment.
globenewswire.com
22 days ago
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands.
zacks.com
24 days ago
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $2.11 per share versus the Zacks Consensus Estimate of a loss of $2.80. This compares to loss of $5.50 per share a year ago.
globenewswire.com
24 days ago
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the first quarter 2025.
globenewswire.com
a month ago
SOUTH SAN FRANCISCO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets.
globenewswire.com
a month ago
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced eight abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/.
businesswire.com
2 months ago
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--LIVMARLI Now Approved in Japan for ALGS and PFIC.
globenewswire.com
2 months ago
SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from three oral presentations at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2025, being held March 26 - 30, 2025 in Beijing, China.
See all news
